#Lutetium 177 Treatment
Text
Dive into the thought process and criteria I used to choose India as my destination for Lutetium PSMA Therapy.
0 notes
Text
2 notes
·
View notes
Text
Lutetium PSMA Therapy in India - Important Things to Know
In recent years, advancements in medical science have paved the way for innovative and targeted therapies to combat various forms of cancer. One such groundbreaking treatment gaining attention is Lutetium PSMA Therapy. Specifically designed for prostate cancer, this therapy utilizes the radioactive isotope Lutetium-177 coupled with PSMA (Prostate-Specific Membrane Antigen) targeting molecules to deliver precise and effective treatment.
Lutetium PSMA Therapy in India is gradually gaining popularity, offering new hope for patients battling advanced prostate cancer. In this article, we explore some important aspects of Lutetium PSMA Therapy in India how it works, and availability of this treatment in India.
Let us understand what is Lutetium PSMA Therapy:
Lutetium-177 is a radioactive element emitting beta radiation Lutetium. PSMA Therapy is a form of targeted radionuclide therapy that addresses prostate cancer by leveraging the unique characteristics of PSMA receptors found on prostate cancer cells. PSMA is a protein expressed at higher levels in prostate cancer cells, making it an ideal target for delivering radiation directly to cancer cells while minimizing damage to surrounding healthy tissues.
While it is not a first-line treatment, Lu-177 PSMA therapy comes into play when other options have proven insufficient or ineffective. Administered under the guidance of a physician, this therapy has shown promising results, offering long-term improvement for many patients with advanced prostate cancer.
How Lutetium PSMA Therapy Works in three steps:
1. Patient Evaluation: Before undergoing Lutetium PSMA Therapy, patients undergo thorough evaluations, including imaging studies and PSA (Prostate-Specific Antigen) blood tests, to determine the extent and nature of the prostate cancer.
2. Radioactive Isotope Administration: Lutetium-177, a beta-emitting radioisotope, is attached to PSMA targeting molecules. When injected into the patient's bloodstream, these molecules seek out and bind to PSMA receptors on prostate cancer cells. This treatment exclusively focuses on cancerous tissue, ensuring that the radiation has no impact on surrounding areas of the body. The unutilized portion of Lu-177 PSMA is expelled from the body through saliva, urine, and faeces, as tumor cells do not retain it.
3. Precision Targeting: The PSMA molecules deliver radiation directly to prostate cancer cells, minimizing damage to healthy tissues. The emitted radiation helps destroy cancer cells, slowing down the progression of the disease.
Now, what is the outcome of Lutetium PSMA Therapy? The effectiveness of Lu177 PSMA therapy hinges on various factors, including the characteristics of your prostate cancer, initial Gleason Score, the extent of disease spread, and responses to previous treatments.
Typically, over 70%-80% of patients experience a decrease in PSA levels and tumor shrinkage following Lu177 PSMA therapy. Additionally, a noteworthy aspect is that nearly all patients report a reduction in pain and an overall improvement in health after receiving the second dose of this therapy.
Important Considerations for Lutetium PSMA Therapy in India:
1. Finding the Right Treatment Center: While Lutetium PSMA therapy is gaining traction in India, only some of the best cancer hospitals in India offer this treatment. It is crucial to identify specialized treatment centers equipped with the necessary infrastructure and expertise. Consultation with some of the best oncologists and healthcare professionals in India will aid in locating appropriate facilities.
2. Patient Eligibility Criteria: Lutetium PSMA therapy is not a one-size-fits-all solution. Factors such as the stage of cancer, previous treatments, and overall health play a crucial role in determining candidacy. Physicians will assess these factors before recommending the therapy.
3. Cost of Lutetium PSMA Therapy in India: Understanding the cost implications of Lutetium PSMA Therapy in India is crucial. In India, the cost of this therapy is generally considered significantly more affordable compared to Western countries. If you are contemplating undergoing Lutetium PSMA therapy in India, seeking guidance from a trustworthy medical tourism facilitator is advisable.
For instance, IndiCure Health Tours stands as a reputable medical travel facilitator in India, capable of linking you with the top healthcare providers in India. Working with a medical tourism facilitator allows for a comprehensive understanding of both the treatment details and associated costs before actual travel, facilitating informed decision-making regarding your medical journey.
Here is a breakdown of some of the factors that can influence the cost of Lutetium PSMA therapy in India:
Your medical condition and history: The stage and aggressiveness of your prostate cancer, as well as any past treatments you have received, can affect the treatment plan and overall cost.
Comorbidities: Any pre-existing medical conditions you have may necessitate additional monitoring or adjustments during treatment, impacting the cost.
Treating doctor and facility: The experience and reputation of the doctor or hospital you choose can influence the cost.
City where you receive treatment: Treatment costs can vary depending on the city and hospital's location.
4. Potential Side Effects: Like any medical intervention, Lutetium PSMA Therapy may have associated side effects. Patients should be well-informed about potential reactions and complications, and healthcare providers will guide them in managing these effects. Given that the therapy is targeted at the tumor, significant adverse effects are typically not observed in patients. However, there are some potential side effects, including dry mouth, dry eyes, nausea, vomiting, fatigue, and reduction in the production of blood cells. It is important to discuss these potential side effects with your healthcare provider so you know what to expect and how to manage them if they arise.
5. Follow-up Care: Post-treatment care and regular follow-up appointments are crucial for monitoring the patient's response to Lutetium PSMA Therapy. This ongoing assessment aids in adjusting treatment plans and addressing any emerging concerns. Regular follow-up ensures you receive optimal care and allows for early detection of any potential issues. While planning your medical travel to India for Lutetium PSMA Therapy, it is recommended to check before hand about the follow up care that will be required, so you can plan ahead about your stay in India accordingly.
Considerations for Medical Visa, Travel, and Stay: When embarking on Lutetium PSMA Therapy in India, several crucial considerations must be addressed, encompassing medical visa acquisition, flight arrangements, ground transportation, and accommodation near the medical facility. These things are crucial for convenience and accessibility during the treatment period.
The pivotal step of obtaining a medical visa necessitates meticulous documentation of the patient's medical condition and treatment plan. To streamline this process, engaging the services of a medical tourism facilitator such as IndiCure Health Tours proves beneficial, as they can aid in obtaining an official medical letter from the doctor or hospital, and facilitating the visa application.
Additionally, IndiCure can assist in securing accommodation tailored to the patient's budget and preferences, alleviating the complexities, and ensuring a seamless trip to India. Post-treatment, it is advisable to consult with the treating doctor to determine the required recovery period in India, allowing for proper planning of the return flight home.
To conclude, Lutetium PSMA Therapy is emerging as a promising option for prostate cancer treatment in India. As with any medical procedure, thorough research, consultation with healthcare professionals and understanding the specific nuances of this therapy are paramount.
If you are looking for Lutetium PSMA Therapy in India and do not know where to start, you can get in touch withIndiCure Health Tours, they are the foremost and best medical tourism company in India. IndiCure partners with the best cancer hospitals in India, along with a team of skilled medical professionals and experienced oncologists. Get in touch with them today to avail Lutetium PSMA Therapy in India.
0 notes
Text
Global Nuclear Medicine Therapeutics Market: Pioneering Healthcare Solutions
A pharmaceutical composition including radioactive elements is known as therapeutic nuclear medicine. In comparison to X-rays and other external radiation imaging technologies, therapeutic nuclear medicines are widely employed as an effective and safer alternative for cancer patients.
Market Size & Growth Rate:
The nuclear medicine therapeutics market was valued at USD 1 billion in 2021 and is expected to reach USD 1.8 billion by 2027, exhibiting a CAGR of 9.6% during the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies.
Market Dynamics:
According to the oncidium foundation, nuclear-therapy accounted for 20% of the global nuclear medicine market in 2019 and is expected to reach 70% by 2030. Nuclear therapeutic is majorly used for the treatment & diagnosis of Cardiovascular Disease (CVD) and cancers. According to WHO-2021, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. The prevalence of these markets has promoted several market players and stakeholders to focus on expanding the overall application of radio-therapeutics. With the expanding application segments of nucleo-emitters, their demand and anticipated rising during the forecast period. It indicates to market players for growth of the nuclear medicine therapeutics market. In addition, various R&D activities in the business space are expected to stimulate the demand for therapeutic nuclear medicine through 2029. For instance,
Click here for full report:
https://www.pharmanucleus.com/reports/nuclear-medicine-therapeutics
Click here for Free Sample:
https://www.pharmanucleus.com/request-sample/1165
Based on the radionuclide therapeutic type, the beta emitters segment grow at a considerable pace during the forecast period. These beta particles like Samarium-153 (SM-153), Iodine-131 (I-131), and Lutetium-177 (LU-177) are known to be lighter than alpha particles like Radium-224 (RA-224), Radium-223 (RA-223) and can penetrate the skin easily
Get more details on this report - Request Free Sample
According to precedence research, by application, the oncology segment accounted major market share of around 40% in 2021 followed by cardiology.
Market Drivers:
Click here for full report:
https://www.pharmanucleus.com/reports/nuclear-medicine-therapeutics
The market players are focusing on various research developments, product launches, and acquisitions that are anticipated to increase the market growth. For instance,
Challenges:
#nuclear medicine#therapeutics#healthcare solutions#radiopharmaceuticals#medical innovation#patient care#nuclear medicine trends#advanced treatments#healthcare breakthroughs#cutting-edge therapies#global market insights
0 notes
Text
How is radioligand therapy developed?
In the changing dynamics of medical science, innovations are the hope for people fighting life-threatening illnesses. Radioligand treatment, commonly denoted to as targeted radionuclide treatment, is one such pioneering method that has been generating waves in the field of oncology. While the name may sound multifaceted, the concept is quite attractive, providing a promising avenue for cancer treatment.
The radioligand therapy market is experiencing growth and is projected to reach USD 13,073.9 million by 2030.
Understanding the Basics
Radioligand treatment includes the utilization of dedicated molecules, called radioligands, which are made to target specific receptors on cancer cells. Such radioligands are fortified with a radioactive isotope, like actinium-225 or lutetium-177. When directed into the patient's body, such radioligands seek out and assign themselves to the receptors on cancer cells, providing a powerful dose of radiation straight to the tumor.
Exactness and Minimalized Side Effects
One of the major benefits of radioligand treatment is its accuracy. Not like conservative radiation treatment, which can affect healthy tissues covering the tumor, radioligand treatment selectively targets cancer cells. This targeted method not only increases the efficiency of treatment but also reduces the harm to healthy tissue, decreasing the danger of side effects.
Prostate Cancer Treatment
Prostate cancer is one of the zones where radioligand treatment has revealed marvelous potential. The FDA sanction of treatments such as Lutathera® for neuroendocrine Xofigo® and tumors for metastatic castration-resistant prostate cancer establishes the rising recognition of radioligand therapy's potential.
The Patient Experience
For patients, radioligand treatment can be the only hope in a complex diagnosis. The treatment is generally managed as an outpatient process, permitting patients to back to their everyday lives comparatively rapidly. Although there might be some side effects, like nausea or fatigue, they are typically wieldy and temporary.
Ongoing Research and Growth
The arena of radioligand treatment is constantly changing. Investigators are discovering new radioligands and radioisotopes, directing to increase the variety of cancers that can be efficiently treated using this method. Clinical trials are ongoing, providing patients the chance to access pioneering treatments.
Challenges
While radioligand treatment has great potential, it is not without challenges. Obtainability and price can be fences for some patients. Moreover, the logistics of managing radioactive materials need particular amenities and expertise.
The U.S. Is Principal Contributor to Market
The market for radioligand therapy in the U.S. will witness a high growth rate during the forecast period. The growth is attributed to the government initiatives for improving chronic disease care and the rising number of specialized cancer hospitals and research centers. For instance, in February 2022, the U.S. president reinvigorated the Cancer Moonshot Program with new goals, to reduce the death rate from cancer by at least 50% over the next 25 years. Thus, the rising number of government initiatives for advancing oncologic practices augments the market for radioligand therapy in the U.S.
0 notes
Text
Prostate Cancer Treatment Market - Future Growth Prospects for the Global Leaders
The latest market report published by Credence Research, Inc. “Global Prostate Cancer Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2022 – 2030. The market for prostate cancer treatment is witnessing substantial growth, with projected revenues to rise from USD 12,415.6 million in 2022 to an estimated USD 21,425.39 million by 2030. This projection signifies a compound annual growth rate (CAGR) of 8.11% from 2023 to 2030. With an increasing global demand for effective treatment methods, the opportunities within this market are expanding.
Prostate cancer is a prevalent malignancy affecting men globally. It originates in the prostate gland, a small walnut-shaped organ that produces seminal fluid. Early detection and timely intervention are crucial for improving patient outcomes. To stay ahead in the battle against prostate cancer, it's essential to comprehend the latest trends and treatments.
Prostate cancer is one of the most common forms of cancer in men, and as a result, there is a significant demand for effective treatments and therapies. In recent years, there has been a notable shift towards more targeted and personalized approaches to prostate cancer treatment. This includes the use of precision medicine, immunotherapy, and advanced radiation therapy techniques, among others. Additionally, ongoing research and development efforts are leading to the discovery of novel drugs and therapies that hold promise in improving patient outcomes.
Prostate Cancer Treatment Market opportunities are steadily emerging as advancements in medical technology and research continue to unfold. With an increasing prevalence of prostate cancer cases globally, the demand for effective treatment options is on the rise. This presents a significant opportunity for pharmaceutical companies, biotechnology firms, and healthcare providers to develop innovative therapies that target specific molecular pathways involved in prostate cancer progression. Moreover, there is immense potential within the field of precision medicine, where personalized treatment approaches based on genetic profiling can revolutionize patient outcomes.
Key Treatment Modalities
1. Surgery
Surgical intervention, such as radical prostatectomy, remains a primary treatment option for localized prostate cancer. It involves the removal of the prostate gland. Advancements in minimally invasive techniques, including robot-assisted surgery, have reduced recovery times and improved outcomes.
2. Radiation Therapy
Radiation therapy, using high-energy X-rays or protons, is another vital component of prostate cancer treatment. Innovations like intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) allow for precise targeting of cancer cells while minimizing damage to surrounding tissues.
3. Hormone Therapy
Hormone therapy, also known as androgen deprivation therapy (ADT), is often used in combination with surgery or radiation. It aims to lower testosterone levels, which can fuel prostate cancer growth. Recent advancements in hormonal therapies have enhanced their effectiveness and reduced side effects.
Emerging Therapies
1. Immunotherapy
Immunotherapy has gained momentum as a promising treatment avenue for advanced prostate cancer. Checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown potential in boosting the immune system's ability to combat cancer cells.
2. Targeted Therapies
Precision medicine has revolutionized cancer treatment. Targeted therapies, like enzalutamide and abiraterone, specifically target pathways involved in prostate cancer growth. These drugs have extended survival rates and improved quality of life for many patients.
3. Radiopharmaceuticals
Radiopharmaceuticals like Lutetium-177 PSMA have emerged as a game-changer in the treatment of metastatic castration-resistant prostate cancer (mCRPC). They deliver highly targeted radiation to cancer cells, offering new hope for patients.
The Role of Research and Clinical Trials
Research plays a pivotal role in advancing prostate cancer treatment. Clinical trials offer patients access to cutting-edge therapies and contribute to the development of future treatments. Stay informed about ongoing trials and potential breakthroughs that could shape the future of prostate cancer care.
Browse 245 pages report Prostate Cancer Treatment Market By Treatment Type (Chemotherapy, Biological Therapy, Hormone Therapy) By Distribution (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) - Growth, Future Prospects & Competitive Analysis, 2016 – 2030 https://www.credenceresearch.com/report/prostate-cancer-treatment-market
List of the prominent players in the Prostate Cancer Treatment Market:
Johnson & Johnson Services, Inc.
Astellas Pharma, Inc.
Eli Lilly and Company
Sanofi
Ipsen Pharma
Bayer AG
AstraZeneca
Valeant Pharmaceuticals International, Inc.
Merck & Co., Inc.
Pfizer Inc.
Conclusion
The landscape of prostate cancer treatment is continually evolving, offering new hope to patients worldwide. By staying informed about the latest advancements, breakthrough therapies, and clinical trials, we can collectively work towards a future where prostate cancer is a manageable condition. Join us in the pursuit of better treatments and improved outcomes for those affected by this disease. Together, we can outrank the challenges posed by prostate cancer.
Why to Buy This Report-
The report provides a qualitative as well as quantitative analysis of the global Prostate Cancer Treatment Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.
Major nations in each region with their import/export statistics
The global Prostate Cancer Treatment Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major player analysis, market growth strategies, and key application areas.
Browse Full Report: https://www.credenceresearch.com/report/prostate-cancer-treatment-market
Visit: https://www.credenceresearch.com/
Related Report: https://www.credenceresearch.com/report/synthetic-ovulation-stimulants-market
Related Report: https://www.credenceresearch.com/report/transfer-membrane-market
Browse Our Blog: https://www.linkedin.com/pulse/prostate-cancer-treatment-market-top-players-size-share-singh-uh35c
About Us -
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.
Contact Us:
Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India
0 notes
Text
Research team develops new system for imaging and treating tumors
Research team develops a new system for imaging and treating tumors.
May 26, 2023 - Thanks to the radiation they emit, radioactive compounds are suited both to imaging and treating cancers. By appropriately combining them in the novel, so-called radionuclide theranostics, both applications can be dovetailed. A radiopharmacy team at Helmholtz-Zentrum Dresden-Rossendorf (HZDR) and Heidelberg University has now presented such a system in the Journal of the American Chemical Society (DOI: 10.1021/jacs.2c08438) that successfully solves one of the biggest problems to date: it works at physiologically relevant temperatures.
“Basically, we can think of it as functioning like a smart key that we use to control our automobiles. We use so-called radionuclides, i.e., unstable atomic nuclei, that spontaneously emit ionized radiation when they decay. We track down the tumor with a diagnostic radionuclide. The targeted internal irradiation close to the diseased tissue is then taken on by a different, therapeutic radionuclide,”
says Dr. Manja Kubeil of HZDR’s Institute of Radiopharmaceutical Cancer Research, describing her theranostic approach.
Her team in the Department of Radionuclide Theragnostics develops exactly these types of substances to track and destroy tumors. Thus, the researchers employ matched pairs of radionuclides which, due to their decomposition characteristics, can be used both for imaging and for tumor therapy on the same target molecule.
The relevant radionuclide is stably bound in what is known as a chelator and linked to a biomolecule by a kind of chemical bridge.
“The word chelator comes from the Latin; its stem relates to being encircled by the claws of a crayfish. We prefer the image of a molecular cage that firmly encloses the radionuclide so that it can’t spread in the body uncontrollably. The target-seeking biomolecule for its part must fit perfectly with the docking site on the cancer cells, just like a key in a lock. The radionuclide then accumulates on the tumor tissue and exclusively develops its destructive impact there – that’s the idea,”
says Kubeil
Stable bonds at practicable temperatures
Lutetium-177, for instance, is particularly suitable as a beta emitter for releasing electrons to treat various tumors as well as a source of gamma rays for imaging. Actinium-225, an alpha emitter that can be used for efficient treatment, is even more effective in destroying tumors and is also very tightly bound by the chelator. Neither radionuclide occurs naturally on Earth. Appropriate methods have to be used to produce them artificially.
Alpha emitters release particles composed of two protons and two neutrons. They are used in cancer therapy because their range in the tissue is very small, but they nonetheless attack and kill cancer cells very effectively thanks to their high energy. Their half-life of seven days in the case of Lutetium-177 and ten in the case of Actinium-225 is ideal for the purpose: it is long enough to enable effective treatment.
New chelator with advantages
So far, there has only been one complexing agent on the market that binds both radionuclides equally well: DOTA. The most frequently used chelator in nuclear medicine is known for its very stable metal complexes. But DOTA has one big disadvantage: only at what are very high temperatures for biochemical conditions, beyond 80 degrees Celsius, is it possible to bond theranostic radionuclides completely.
“If you are working with protein derivatives, these temperatures are way too high because even at 40 degrees Celsius denaturation kicks in: they are destroyed. Our new chelator system functions reliably at these lower temperatures,”
Kubeil is pleased to report.
Moreover, under these milder conditions, it achieves faster radiolabeling than the known chelators. Another advantage is that the new system efficiently attaches to various bioconjugates. This means an increase in the choice of docking sites on diseased tissue. The newly developed chelator could thus form the basis for new modular and personalized pharmaceutical systems that could be geared towards different fields for imaging and therapy by simply exchanging partial chemical structures.
Publication:
P. Cieslik, M. Kubeil, K. Zarschler, M. Ullrich, F. Brandt, K. Anger, H. Wadepohl, K. Kopka, M. Bachmann, J. Pietzsch, H. Stephan, P. Comba, Toward Personalized Medicine: One Chelator for Imaging and Therapy with Lutetium-177 and Actinium-225, Journal of the American Chemical Society, 2022 (DOI: 10.1021/jacs.2c08438)
Read the full article
1 note
·
View note
Text
Peptide Drug Conjugates Market By Product, By Technology, By Application, By Region, And Segment Forecast 2023 to 2033
The global peptide drug conjugates market is expected to be worth US$ 861.12 million in 2023 and US$ 5,331.83 million by 2033. Over the forecast period of 2023 to 2033, the predicted growth rate is about 20%. The growth of the market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.
According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to cancer. Furthermore, as per cancer.gov, by 2040, the number of new cancer cases patients per year is estimated to reach 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.
Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as Novartis’s Lutathera (lutetium Lu 177) indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA’s accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.
Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can be attributed to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.
Key Takeaways from the Market Study
By product, Lutathera segment accounted for the largest share of 80.5% in 2022
Based on type, therapeutic segment dominated the peptide drug conjugates market with the revenue share of 82.3%.
North America dominated the global market in 2022 with a revenue share of 45.62%.
Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period.
“Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive the market growth.,” says an analyst at Future Market Insights.
For more information: https://www.futuremarketinsights.com/reports/peptide-drug-conjugates-market
Key Market Players
Major players are channelling efforts toward expanding their production capacities to strengthen their market share and cater to the growing demand. Market expansion is anticipated to be aided by the growing number of partnerships and collaborations among key players that are looking to increase their presence in the market. Key players in the Peptide Drug Conjugates market are Novartis AG; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Oncopeptides AB; Angiochem Inc.; Innovasium Soricimed Biopharma; and Theratechnologies. Some of the recent key developments among key players are:
In November 2022, Cybrexa Therapeutics and Exelixis, Inc. announced the collaboration agreement providing Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. This initiative is expected to expand its clinical pipeline for targeted drug therapy.
In December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Peptide Drug Conjugates market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Key Market Segments Covered in the Global Peptide Drug Conjugates Market
By Product:
Lutetium
Melflufen
ANG1005
BT1718
CBX-12
Other Pipeline Products
By Type:
Therapeutic Peptide Drug Conjugates
Diagnostic Peptide Drug Conjugates
0 notes
Text
Best Nuclear Medicine Treatment in Trivandrum, India | KIMSHEALTH Hospital
Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease
Procedures & Treatments
Nuclear medicine, in a sense, is “radiology done inside out” or “endoradiology” because it records radiation emitting from within the body rather than radiation that is generated by external sources like X-rays. In addition, nuclear medicine scans differ from radiology as the emphasis is not on imaging anatomy but the function and for such reason, it is called a physiological imaging modality.
Single Photon Emission Computed Tomography or SPECT and Positron Emission Tomography or PET scans are the two most common imaging modalities in nuclear medicine
HEART:
Myocardial viability PET and SPECT
Adenosine Stress perfusion scan
Stress Dobutamine Myocardial MIBI perfusion SPECT
Stress and Rest myocardial perfusion SPECT
MUGA scan
BRAIN:
FDG brain PET CT
F-18 DOPA PET CT
Brain perfusion SPECT
Ictal and interIctal SPECT
Trodat SPECT
Tumour Viability Study
SKELETAL SYSTEM:
Three Phase Bone scan
Whole body Bone scan
F18 Fluoride Bone PET CT.
FDG PET prosthesis/infection Imaging.
Graft viability imaging
GASTROINTESTINAL:
Salivary scan
GE Reflux scan
Gastric Emptying Time
RBC — GI Bleed scan
Meckel’s scan
Whole body DOTA PET CT
HEPATOBILIARY/LIVER — SPLEEN:
Liver Spleen scan
RBC Blood pool scan
Hepatobiliary (HIDA) scan
MAA Sunt
GENITOURINARY:
Diuretic DTPA Renal scan
GFR Estimation
EC Renal scan (ERPF)
DMSA Cortical Renal scan
Captopril Renal scan
VU Reflux study
Renal Transplant study
Lymphoscintigraphy for Chyluria
Whole body PSMA PET CT
ENDOCRINE:
Technetium Thyroid scan
MIBI Thyroid scan
MIBI Parathyroid Scan
MIBG scan
Octreotide SPECT CT
ONCOLOGY:
Whole body FDG PET CT
Whole body Gallium 68 DOTA scan
Whole body Gallium 68 PSMA scan
F-18 Choline PET CT
Whole body iodine scan
Post therapy scan
F-18 DOPA PET CT
Senthinal lymphoscintrigrapy
Scintimammography
HSA scan for protein leak
INFECTION IMAGING:
Whole body FDG PET infection Imaging
Gallium 67 scan
99mTc Ubiquicidin Imaging
RESPIRATORY:
Lung Perfusion Scan
Ventilation — Perfusion (V/Q) scan
Quantitative lung ventilation
Mucociliary clearance study
Ventilation
BLOOD:
Lymphoscintigraphy for Lymphoedema.
Sentinel Node Mapping
RADIONUCLIDE THERAPY:
Radio lodine treatment for Thyrotoxicosis ( < 10 mci)
Radio lodine treatment for Thyrotoxicosis ( > 10 mci)
Radioiodine therapy for Ca. Thyroid ( <100 mci )
Radioiodine therapy for Ca. Thyroid ( >100 mci )
rTSH Radioiodine therapy for Ca thyroid
177 Lutetium DOTA therapy for Neuroendocrine tumors.
177 Lutetium PSMA therapy for Ca. Prostate
Samarium Skeletal Pain Palliative Therapy
90 Yttrium Radiation Synovectomy.
131 Iodine Lipidiol TARE therapy for HCC.
90 Yttrium Lipidiol TARE therapy
Strontium 89 skeletal pain palliative therapy
PET SCAN (OUTSIDE ) REVIEW
CT CONTRAST (PET CT)
omnipaque
visipaque
oral contrast (PET CT)
RBC BLOOD POOL
F CHOLINE
0 notes
Text
Prostate Cancer Drug Shortage Leaves Some With Uncertainty#Prostate #Cancer #Drug #Shortage #Leaves #Uncertainty
A radioligand treatment approved for certain men with metastatic castration-resistant prostate cancer (CRPC) is in short supply because of manufacturing and delivery issues, according to the US Food and Drug Administration (FDA).
The therapy lutetium Lu 177 vipivotide tetraxetan (Pluvicto), approved in March 2022, will remain in limited supply until the drug’s manufacturer, Novartis, can ramp up…
View On WordPress
0 notes
Text
#superspecialitycare#Outcome of Lu177 PSMA Therapy in India#Cost of Lutetium or Lu177 PSMA Therapy in India
0 notes
Text
The Nuclear Medicine Therapy Centre at FMRI is one of the pioneers in medical tourism for patients with prostate cancer and neuroendocrine tumors. The center provides you with an effortless way to understand and go through your treatment process including pick-up/drop, and visa on arrival. We ensure that the treatment is effortless and budget-friendly and are there with you to help navigate everything.
0 notes
Text
Lutetium-177 PSMA therapy is a new, cutting-edge treatment for prostate cancer that is showing great promise. This therapy uses a radioactive isotope called lutetium-177, which targets and kills cancer cells while sparing healthy tissue. Lutetium-177 PSMA therapy is currently being used in clinical trials and has been shown to be effective in treating prostate cancer. This treatment is non-invasive just like Actinium (Ac225) PSMA Therapy and has very few side effects, making it an attractive option for patients with this disease.
TAG- Outcome of Lu177 PSMA Therapy in India, Cost of Lutetium or Lu177 PSMA Therapy in India
0 notes
Text
Trends | Future and Growth for Prostate Health Market
Prostate health is an important concern for men. The prostate is a small gland that is part of the male reproductive system. It is located just below the bladder and in front of the rectum. Its primary function is to produce fluid that transports sperm during ejaculation. Prostate health is important for a number of reasons.
An enlarged prostate can cause discomfort and can lead to urinary problems such as frequent urination, difficulty urinating, or a weak urine stream. An enlarged prostate can also increase the risk of prostate cancer. Other risks for prostate cancer include age, family history, and ethnicity.
There are a number of steps men can take to promote prostate health and reduce their risk of prostate cancer. Eating a balanced diet and engaging in regular physical activity can help keep the prostate healthy. Additionally, men should have a yearly prostate exam to check for any signs of prostate cancer.
According to a research report "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" published by MarketsandMarkets, the global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period.
Request for assumptions & how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=107055093
Market Growth Drivers
Growing prevalence of prostate cancer and BPH
Market Growth Opportunities
Emerging economies (such as China, India, Brazil, and Mexico) are projected to offer significant growth opportunitie
Market Challenges
Low awareness regarding prostate health among men
Industry Trends
This represents an annual growth of about 7% and a total increase of 58% from 2010. Obesity and Benign Prostatic Hyperplasia (BPH) are closely associated.
Finasteride and Dutasteride (among other 5-ARIs) convert testosterone to dihydrotestosterone. These drugs also decrease the synthesis of several neuroactive steroids, but the modulation of the neuroendocrine stress response may lead to depression. Other side effects of 5-ARIs are gynecomastia, impotence, and reduced libido and ejaculate volume.
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107055093
Some of the prominent players operating in the prostate health market are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan), and other players.
Research Developments
In March 2022, Lantheus Holdings, Inc. (US) collaborated with Novartis AG (Switzerland) to include PYLARIFY (piflufolastat F18) in prostate cancer clinical trials with Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to support prostate cancer clinical development.
In March 2022, Novartis AG (Switzerland) received approval for PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) by FDA for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).
In January 2021, Pharex Tamsulosin for the treatment of benign prostatic hyperplasia was introduced by PHAREX Health Corporation (Philippines) in collaboration with the Philippine Urological Association (PUA).
In October 2020, Israeli medical device manufacturer Butterfly Medical raised USD 7 million in a Series B round to develop an anatomically shaped nitinol implant positioned in the prostatic urethra to relieve BPH symptoms
Content Source:
1. https://www.prnewswire.com/news-releases/prostate-health-market-worth-48-9-billion-by-2026--exclusive-report-by-marketsandmarkets-301443961.html
1 note
·
View note
Text
Peptide Receptor Radionuclide Therapy (PRRT) Market end-user demand, trend, new innovations, global forecast to 2032
This Peptide Receptor Radionuclide Therapy market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Peptide Receptor Radionuclide Therapy Prrt market.
Advancement and growing researches in the medical industry leads to a dramatic surge in the availability of new cancer treatment options. Radiation therapies and targeted therapy is showing significant promise in cancer treatment. For example, peptide receptor radionuclide therapy (PRRT) had recently approved the neuroendocrine tumors and projecting significant growth in the cancer treatment market. Peptide receptor radionuclide therapy (PRRT) is radioisotope or molecular therapy used to treat neuroendocrine tumors (NETs).
Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10376
Peptide receptor radionuclide therapy (PRRT) is recommended for the somatostatin receptor-positive gastroenteropancreatic NETs affected patients. Peptide receptor radionuclide therapy (PRRT) is a targeted therapy designed to slow the progression of gastroenteropancreatic NET and limiting radiation exposure to healthy tissue. Lutathera (lutetium Lu 177 Oxodotreotide) was the first drug approved for the peptide receptor radionuclide therapy (PRRT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In September 2017, the European Commission approved Lutathera peptide receptor radionuclide therapy (PRRT) drug manufactured by Advanced Accelerator Applications S.A. Although, the U.S. Food and Drug Administration (FDA) was approved LUTATHERA in January 2018. Growing clinical trials and development activities to create therapeutic radiopharmaceuticals expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market over the forecast period.
Peptide Receptor Radionuclide Therapy (PRRT) Market: Drivers and Restraints-
Increasing prevalence of the neuroendocrine tumors expected to impel the demand for peptide receptor radionuclide therapy (PRRT) as an increasing number of the patient pool. Establishment of reimbursement policies for Lutathera favors the demand for peptide receptor radionuclide therapy (PRRT). A temporary insurance/billing code was used for the peptide receptor radionuclide therapy (PRRT) till 2018. Moreover, increasing clinical trials for the new radiopharmaceuticals drugs approval for cancer therapy expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market.
Increasing government and private organizations funding for cancer drugs and therapy development is another major factor expected to propel the growth of the peptide receptor radionuclide therapy (PRRT) market. Moreover, growing manufacturer’s interest in the radiopharmaceutical and cancer market flourish the growth of the peptide receptor radionuclide therapy (PRRT) market. Side effects such as the transient decrease in blood counts, nausea and others associated with PRRT expected to hamper the growth of the peptide receptor radionuclide therapy (PRRT) market.
Peptide Receptor Radionuclide Therapy (PRRT) Market: Overview
Peptide receptor radionuclide therapy (PRRT) a special type of radiopharmaceutical which injected into the patients’ bloodstream. This radiopeptide travels and binds to neuroendocrine tumor cells and provide a high dose of radiation directly to the cancer cell. Big pharmaceutical market players are focusing to enter in the radiopharmaceutical market. For instance, In October 2017, Novartis AG acquired Advanced Accelerator Applications (AAA) for $3.9 billion to expand oncology portfolio. This acquisition was valuable for Lutathera radiopharmaceutical candidates which were under FDA review in 2018.
Peptide Receptor Radionuclide Therapy (PRRT) Market: Region-wise Outlook
North America and Europe region are expected to grebe more than half of the market share for peptide receptor radionuclide therapy. Increasing clinical trials for radiopharmaceuticals and growing demand for the targeted therapy for cancer are the major factors driving the growth of the peptide receptor radionuclide therapy market in the U.S. and European countries. The Asia pacific peptide receptor radionuclide therapy market expected to grow with significant growth rate as growing demand for advance treatment option and comparatively high prevalence of cancer in India and China.
Peptide Receptor Radionuclide Therapy (PRRT) Market: Key Market Participants
Example of some market players participants in global peptide receptor radionuclide therapy (PRRT) market find across the value chain are Advanced Accelerator Applications (AAA) (Novartis AG) and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on:
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes:
North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (India, China ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Peptide Receptor Radionuclide Therapy (PRRT) Market: Segmentation
On the basis of indication, peptide receptor radionuclide therapy (PRRT) market can be segmented as:
Foregut Neuroendocrine Tumors
Midgut Neuroendocrine Tumors
Hindgut Neuroendocrine Tumors
On the basis of end user, peptide receptor radionuclide therapy (PRRT) market can be segmented as:
Hospitals
Ambulatory Surgical Centers
Cancer Care Centers
For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-10376
Report highlights:
Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
#Peptide Receptor Radionuclide Therapy (PRRT) Market Market#Peptide Receptor Radionuclide Therapy (PRRT) Market Market Size#Peptide Receptor Radionuclide Therapy (PRRT) Market Market Growth
0 notes
Text
Medical Disposables Market is Booming Worldwide by 2033 | Growth, Share, Demand and Analysis Forecasts
The global peptide drug conjugates market is expected to be worth US$ 861.12 million in 2023 and US$ 5,331.83 million by 2033. Over the forecast period of 2023 to 2033, the predicted growth rate is about 20%. The growth of the market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.
According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to cancer. Furthermore, as per cancer.gov, by 2040, the number of new cancer cases patients per year is estimated to reach 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.
Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as Novartis’s Lutathera (lutetium Lu 177) indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA’s accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.
Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can be attributed to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.
Key Takeaways from the Market Study
By product, Lutathera segment accounted for the largest share of 80.5% in 2022
Based on type, therapeutic segment dominated the peptide drug conjugates market with the revenue share of 82.3%.
North America dominated the global market in 2022 with a revenue share of 45.62%.
Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period.
“Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive the market growth.,” says an analyst at Future Market Insights.
For More Information: https://www.futuremarketinsights.com/reports/peptide-drug-conjugates-market
Key Market Players
Major players are channelling efforts toward expanding their production capacities to strengthen their market share and cater to the growing demand. Market expansion is anticipated to be aided by the growing number of partnerships and collaborations among key players that are looking to increase their presence in the market. Key players in the Peptide Drug Conjugates market are Novartis AG; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Oncopeptides AB; Angiochem Inc.; Innovasium Soricimed Biopharma; and Theratechnologies. Some of the recent key developments among key players are:
In November 2022, Cybrexa Therapeutics and Exelixis, Inc. announced the collaboration agreement providing Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. This initiative is expected to expand its clinical pipeline for targeted drug therapy.
In December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Peptide Drug Conjugates market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
0 notes
Last Seen Blogs
jaegerjaw
GrimmjowCentric
meltyice
☽
drawingtutorial2017
Untitled
dark-academic-dead-poet
this_user_likes_poetry
lazyfigure
Blog